Patients with advanced colorectal cancer (CRC) still depend on chemotherapy regimens
that are associated with significant limitations, including resistance and toxicity. The …

Treatment of colorectal cancer mostly relies on traditional therapeutic approaches, such as
surgery and chemotherapy. Limited options of targeted therapy for colorectal cancer …

Purpose Dasatinib inhibits src family kinases and has anti-angiogenic properties. We
conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab …

Purpose: Aberrant activation of the intracellular tyrosine kinase Src has been implicated as a
mechanism of acquired chemotherapy resistance in metastatic colorectal cancer (mCRC) …

Metastatic colorectal cancer (mCRC) is the second leading cause of cancer deaths in the
United States. More than 50% of patients with mCRC harbor mutations of the oncogenic …

Purpose: Despite the availability of several active combination regimens for advanced
colorectal cancer (CRC), the 5-year survival rate remains poor at less than 10%, supporting …

LB-69 Introduction: Dasatinib is an oral tyrosine kinase inhibitor that potently inhibits Src, a
nonreceptor tyrosine kinase that affects proliferation, angiogenesis, migration, invasion, and …

Inhibitors of apoptosis proteins (IAPs) are intracellular proteins, with important roles in
regulating cell death, inflammation, and immunity. Here, we examined the clinical and …

Apoptosis resistance contributes to treatment failure in colorectal cancer (CRC). New
treatments that reinstate apoptosis competency have potential to improve patient outcome …

Late‐stage colorectal cancer (CRC) is still a clinically challenging problem. The activity of
the tumor suppressor p53 is regulated via post‐translational modifications (PTMs). While the …